ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)
Chater, J., Xu, R., Bugano, D., Chen, J., Lordick, F., Paulson, S., Tabernero, J., …Shah, M. (2026). ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC). Oncology Research and Treatment, 49, 208-208 https://doi.org/10.1200/JCO.2026.44.2_suppl.TPS460 (Meeting abstract).
Deixa un comentari